Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes tumors more aggressive and difficult to treat. Colon cancer is the third ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently approved as a second-line or later treatment for metastatic breast cancer has interim clinical data showing it helped patients ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant and clinically meaningful improvement in main goal for its gastric or ...

AstraZeneca will record sales in other countries worldwide, for which profits shared with Daiichi Sankyo will be recorded within cost of sales. Daiichi Sankyo will manufacture and supply DS-1062.

Datopotamab deruxtecan has been granted Breakthrough Therapy Designation, or BTD, in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor ...

Enhertu + pertuzumab showed significant PFS improvement vs. THP in HER2+ metastatic breast cancer in DESTINY-Breast09 trial. Interim OS data favored Enhertu combo; safety profile aligned with ...